Benchling adds another megaround into the fold, looking even more unicorn-y as a possible IPO approaches
Touting its mission to revolutionize R&D by bringing drug development into the cloud, Benchling has earned its unicorn horn from investors hungry for something new. A new round of financing will now drive that eye-popping valuation even higher.
Just seven months after raising $200 million from investors in a Series E, valuing the R&D cloud software developer at just over $4 billion in April, Benchling raised $100 million in a Series F round, valuing the company at a tidy $6.1 billion. And this doesn’t take into consideration that Benchling was worth under $1 billion last April, according to Forbes — just after the Covid-19 pandemic hit the world stage.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.